Related Experiment Video

Updated: Jan 5, 2026

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise
05:06

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise

Published on: July 14, 2023

2.3K

The Preventive Effect of IL-1beta Antagonist on Diabetic Peripheral Neuropathy

Zheng Hangping1, Han Ling2,3, Ji Lijin1

  • 1Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University 12# Middle Wulumuqi Road, Shanghai, China.

Endocrine, Metabolic & Immune Disorders Drug Targets
|October 24, 2019
PubMed
Abstract

Insights

High levels of circulating Interleukin-1beta (IL-1beta) are linked to diabetic peripheral neuropathy (DPN). Treatment with an interleukin-1 receptor antagonist (IL-1RA) protected nerve structure in a rat model, suggesting a potential therapeutic strategy.

Area of Science:

  • Neuroscience
  • Endocrinology
  • Immunology

Background:

  • Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus.
  • The role of inflammation, particularly Interleukin-1beta (IL-1beta), in DPN pathogenesis is increasingly recognized.

Purpose of the Study:

  • To investigate the relationship between IL-1beta and DPN.
  • To evaluate the therapeutic potential of blocking IL-1 signaling in a diabetic neuropathy animal model.

Main Methods:

  • A rat model of DPN was established using streptozotocin (STZ).
  • Diabetic rats were treated with either saline or an interleukin-1 receptor antagonist (IL-1RA).
  • Sciatic nerve morphology was assessed using light and transmission electron microscopy.

Main Results:

  • Transmission electron microscopy revealed significant protection of myelin and axon ultrastructure in the IL-1RA treated group compared to diabetic controls.
  • IL-1RA treatment mitigated the structural damage associated with diabetic neuropathy.

Conclusions:

  • Elevated circulating IL-1beta levels are potentially associated with DPN risk.
  • Anti-IL-1 therapy, using IL-1RA, demonstrates a potential preventative strategy for diabetic neuropathy.
Keywords:
Diabetic peripheral neuropathyIL-1RAIL-1betainflammationpreventionrats.

More Related Videos

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

888
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.3K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
537
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
798